Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by digger144on Sep 08, 2012 2:20pm
256 Views
Post# 20337910

West Side Story...

West Side Story...

The following Presentation, illustrates what the delay of Underground Production at the Black Fox Mine is all about:

Go to slide 16.

https://www.snl.com/Cache/1001168718.PDF?D=&O=PDF&IID=4288058&Y=&T=&FID=1001168718

The green is the completed ramping system which will allow access to the stope (red) and the grey is future expansion of the ramping system which should be completed by early November, 2012.

The grey is causing the delay which as mentioned by others is a "good thing". This most prolific stope has proved to be much larger and deeper than initial findings which justifies the delay....the market should push past this.

In order to get the mining sequence correct and extract the most resources possible from this stope, initial access must be deeper into the Mine...Nice!

They had planned to access ore with their present infrastructure to-date and would of been into the ore and producing right now which would of brought the numbers up accordingly.

Upon further review it is no doubt a very good decision by the Management Team and we will be rewarded in regards to future gold production which will come in the form of high-grade (6g/t.) feed at an average of 400-500 t.p.d. by February, 2013.

Digger144

Bullboard Posts